Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon P Langdon

Showing results (11-20 of 89) with videos related to

Pageof 9
Sort By:
Onkologie|November 6, 2009
The importance of growth factors and steroid hormones in ovarian cancerSimon P Langdon, Dana Faratian, David J Harrison
Breast (Edinburgh, Scotland)|October 3, 2015
Technical innovation in adjuvant radiotherapy: Evolution and evaluation of new treatments for today and tomorrowIan H Kunkler, Carol Ward, Simon P Langdon
Discovery Medicine|October 1, 2009
How can systems pathology help us personalize cancer therapy?Dana Faratian, Simon P Langdon, David J Harrison
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancerSarah J Taylor, Mark J Arends, Simon P Langdon
Experimental Cell Research|February 15, 2005
Role of TGF alpha stimulation of the ERK, PI3 kinase and PLC gamma pathways in ovarian cancer growth and migrationJane M Sewell, John F Smyth, Simon P Langdon
Expert Review of Anticancer Therapy|December 15, 2016
Endocrine therapy in epithelial ovarian cancerSimon P Langdon, Charlie Gourley, Hani Gabra, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapiesPoornima Paramasivan, Ibrahim H Kankia, Simon P Langdon, et al.
Cancers|June 26, 2020
Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian CancerSimon P Langdon, C Simon Herrington, Robert L Hollis, et al.
Breast Cancer Research : BCR|December 24, 2025
The significance of molecular heterogeneity in breast cancer batch correction and dataset integrationNicholas Moir, Dominic A Pearce, Simon P Langdon, et al.
Frontiers in Oncology|February 20, 2014
Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinationsAlexey Goltsov, Simon P Langdon, Gregory Goltsov, et al.
Pageof 9

Showing results (11-20 of 89) with videos related to

Sort By:
Pageof 9
Onkologie|November 6, 2009
The importance of growth factors and steroid hormones in ovarian cancerSimon P Langdon, Dana Faratian, David J Harrison
Breast (Edinburgh, Scotland)|October 3, 2015
Technical innovation in adjuvant radiotherapy: Evolution and evaluation of new treatments for today and tomorrowIan H Kunkler, Carol Ward, Simon P Langdon
Discovery Medicine|October 1, 2009
How can systems pathology help us personalize cancer therapy?Dana Faratian, Simon P Langdon, David J Harrison
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancerSarah J Taylor, Mark J Arends, Simon P Langdon
Experimental Cell Research|February 15, 2005
Role of TGF alpha stimulation of the ERK, PI3 kinase and PLC gamma pathways in ovarian cancer growth and migrationJane M Sewell, John F Smyth, Simon P Langdon
Expert Review of Anticancer Therapy|December 15, 2016
Endocrine therapy in epithelial ovarian cancerSimon P Langdon, Charlie Gourley, Hani Gabra, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapiesPoornima Paramasivan, Ibrahim H Kankia, Simon P Langdon, et al.
Cancers|June 26, 2020
Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian CancerSimon P Langdon, C Simon Herrington, Robert L Hollis, et al.
Breast Cancer Research : BCR|December 24, 2025
The significance of molecular heterogeneity in breast cancer batch correction and dataset integrationNicholas Moir, Dominic A Pearce, Simon P Langdon, et al.
Frontiers in Oncology|February 20, 2014
Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinationsAlexey Goltsov, Simon P Langdon, Gregory Goltsov, et al.
Pageof 9